Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

AbbVie

AbbVie Inc.

HQ
United States
Status
active
Listing
Listed · ABBV
Founded
2013
Current stage
commercial

sec.govregistryverified 2026-09-23

Notes on the record

Acquirer in D003-abbvie-gilgamesh-2025 and counterparty to the 2024 option in D004-abbvie-gilgamesh-option-2024. Added 2026-09-23 so Issue 15 can carry the ABBVIE tag: entity tags derive from this file and the build refuses a tag with no row, which is DATA LAYER rule 1 enforced at build time. Lead psychedelic asset is bretisilocin (GM-2505), renamed ABBV-2505 after the acquisition closed in October 2025.

Assets

No asset in data/assets.csv names this company as owner.

Registered trials

No row in data/trials.csv resolves to this company's assets.

Deals

In the briefing

1 issue tagged ABBVIE.